New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
07:31 EDTARII, PSX, HFC, BRK.A, GBX, VLO, WNR, TRN, TSO, MROOil volatility extends beyond Bakken, WSJ says
Oil from North Dakota's Bakken Shale has already been identified as combustible following train derailments in the past year, but high gas levels also are affecting oil from Colorado's Niobrara Shale and Texas' Eagle Ford and Permian areas, said The Wall Street Journal, citing energy executives and experts. Valero Energy (VLO), which is investing more than half a billion dollars to add special equipment at several plants so it can process more light oil, says two of its refineries received batches of unexpectedly gassy oil and had to slow production to deal with it and others will have to make the costly shift, according to McKinsey director Matt Rogers, the report noted. Other publicly traded refiners include HollyFrontier (HFC), Marathon Oil (MRO), Phillips 66 (PSX), Tesoro (TSO), and Western Refining (WNR). In the midst of an increased focus on safety for crude carrying trains, Berkshire Hathaway's (BRK.A) BNSF Railway has previously said it intends to purchase up to 5,000 new crude tank cars and seek cars with more safety features. Publicly traded companies in the tank car space include Greenbrier Companies (GBX), American Railcar Industries (ARII) and Trinity Industries (TRN). Reference Link
News For A From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 6, 2015
07:23 EDTAAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
October 5, 2015
05:29 EDTADako announces FDA approval of new companion diagnostic assay
Subscribe for More Information
October 2, 2015
15:57 EDTALabCorp to offer PD-L1 companion diagnostic
Subscribe for More Information
15:43 EDTAQuest Diagnostics introduces Dako's PD-L1 companion diagnostic for KEYTRUDA
Subscribe for More Information
15:25 EDTAAgilent's Dako confirms FDA approval of NSCLC diagnostic
Dako, an Agilent Technologies (A) company and a worldwide provider of cancer diagnostics, announced the FDA approval of a new companion diagnostic assay that can reveal whether a patient with advanced non-small cell lung cancer, or NSCLC, is likely to respond to a new form of treatment. The approval of PD-L1 IHC 22C3 pharmDx strengthens Dako's portfolio of companion diagnostics and the company's leadership position in developing and commercializing companion diagnostic products. Dako developed PD-L1 IHC 22C3 pharmDx in partnership with Merck (MRK), maker of the anti-PD-1 therapy Keytruda. The FDA approved PD-L1 IHC 22C3 pharmDx for use in the United States. Dako hopes to gain regulatory approval for the new diagnostic in Canada, Europe and other jurisdictions next year.
September 24, 2015
17:04 EDTAMerck, Pfizer to collaborate with Agilent's Dako on Avelumab diagnostic
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use